• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Assessment of the Japan Generics Industry Product Image

Assessment of the Japan Generics Industry

  • ID: 2196148
  • March 2012
  • Region: Japan
  • 25 Pages
  • Smart Research Insights

While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs. The country’s government has set an ambitious goal to enhance the generics penetration to at least 30% of all ethical drugs by the end of 2012. The segment’s growth is expected to be driven by various factors such as a rapidly aging population, government initiatives to reduce healthcare spending and key drug patent expiries. The huge potential of this market has also attracted foreign players to this relatively untapped market, as they have collaborated or acquired stake in some of the domestic companies. Many Japanese hospitals are adopting the Diagnosis Procedure Combination (DPC), a flat-fee system that is promoting the penetration of generics in Japan.

Why should the report be purchased?

Our report ‘Assessment of the Japan Generics Industry’ analyzes the structure and positioning of the generics sector within the Japanese pharmaceutical industry. It highlights key trends and drivers of the generics drug industry in Japan. It analyses the key challenges being faced and the government initiatives being taken to overcome barriers and READ MORE >

1. Introduction: Japan Pharmaceutical Market

2. Japan Generic Drugs Industry: Overview
a. Performance Analysis
b. Regulatory Environment

3. Emerging Trends & Drivers

4. Industry Challenges

5. Competitive Landscape
a. Taiyo Pharmaceutical
b. Sawai Pharmaceuticals
c. TOWA Pharmaceutical
d. Nichi-Iko
e. Nippon Chemiphar

6. Future Outlook

7. Research Methodology

8. About Smart Research Insights

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos